MONITORING OF SIDE EFFECTS OF ANTI-TUBERCULOSIS DRUGS ON THE CASES OF PULMONARY TB PATIENT IN CIKAMPEK PRIVATE HOSPITAL
DOI:
https://doi.org/10.61841/ht8p2w10Keywords:
Mycobacterium tuberculosis, pulmonary TB, Drug Side EffectsAbstract
In Indonesia Tuberculosis (TB) is still a serious health problem and shows an increase in cases from year to year. West Java (0.7%) province with the highest pulmonary TB, given the increasing drug-related problems (Drug Related Problems) against antituberculosis drugs in the category of adverse drug reactions (Adverse Drug Reactins). This study aims to obtain information on the side effects of antituberculosis drugs experienced by patients with new cases of pulmonary TB in Cikampek Private Hospital. The research method is a prospective observational monitoring of drug side effects on a regular basis every week for 1 month of intensive treatment. The number of samples in this study were 83 patients. The results showed that the percentage of side effects of antituberculosis drugs experienced by TB sufferers during intensive treatment were red in the urine (100%), nausea (34.85%), spasms (27.27%), tingling (18.18%) , dizziness (25.76%) and no appetite (15.15%). Fisher's test analysis results showed that statistically the socio-demographic characteristics of the respondents evaluated did not affect the incidence of ADRs, but clinically there was a significant relationship.
Downloads
References
[1] Abbas, A. (2017). “Monitoring Efek Samping Obat Anti-Tuberkulosis (OAT) Pada Pengobatan Tahap Intensif Penderita TB Paru Di Kota Makassar”.Journal of Agromedicine and Medical Sciences Vol. 3 No. 1;19-24
[2] Athira, B.et al. (Maret 2015).“A study on Adverse Drug Reactions to First Line Anti-tubercular Drugs in DOTS Therapy”.International Journal of Pharmacology and Clinical Sciences.Vol.4, p :7-11.
[3] Badan Penelitian dan Pengembangan Kesehatan.(2013). Riset Kesehatan Dasar (RISKESDAS) 2013. Kementerian Kesehatan RI, 69-70
[4] Badan Pusat Statistik Provinsi Jawa Barat. (2012).Profil Kesehatan Propinsi Jawa Barat Tahun 2012.
[5] Bent, V.& Egherts.(2007). “Drug Related Problems: Definitions and classification”. EJHP Practice. Volume 13: 62-64
[6] Cholisoh, Z. (2017). Implementasi Farmakovigilans dalam AsuhanKefarmasian. Makalah pada Seminar Nasional dan Worshop Kefarmasian Meningkatkan Peran Farmasis melalui Good Communication Practice dalam mendukung Implementasi Farmakovigilans, kerjasama antara Universitas Darussalam Gontor dan IAI PC Ponorogo, 12 Maret 2017
[7] Depkes RI, (2005). Pharmaceitical Care Untuk Penyakit Tuberkulosis.Direktorat Bina Farmasi Komunitas dan Klinik.
[8] Dipiro, J.T. et al.,(2008). Pharmacotherapy A Pathophysiological Approach. Seventh Edition., USA: McGraw Hill Medical.
[9] Gholami, K., Kamali, E., Hajiabdolbagh, M., Shalviri, G. (2006).“Evaluation of Anti-tuberculosis Induced Adverse Reactions in Hospitalized Patients”.Pharmacy Practice; 4(3): 134-138.
[10] Honnaddi, O.C. et al. (2016). “Adverse Drug Reactions to First Line Anti-Tubercular Drugs - A Pharmacovigilance Study”.International Journal of Pharmacological Research. IJPR
[11] Kementerian Kesehatan RI. 2014. Pedoman Nasional Pengendalian Tuberkulosis. Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan, Jakarta Volume 6 Issue 02
[12] Kurnia, F. et al.(2012).“Adverse Drug Reactions of Primary Anti-tuberculosis Drugs Among Tuberculosis Patiens Treated in Chest Clinic”.International Journal of Pharmacy & Life Sciences, Vol. 3, Issuee 1: Jan, 1331-1338
[13] Kusumawardhani.(2015). Evaluasi Penggunaan Obat Anti Tuberkulosis pada Pasein Rawat Jalan di Rumah Sakit Paru Sidawangi Jawa Barat Periode Januari-Juni 2015. Naskah Publikasi Karya Tulis Ilmiah. Fakultas Kedokteran dan Ilmu Kesehatan Universitas Mummadiyah Yogyakarta.
[14] Lee, A. (Ed), (2001). Adverse Drug Reactions. Pharmaceutical Press, London
[15] Marra, F. et al.(2007).“Adverse drug reactions associated with first-line anti-tuberculosis drug regimens.The International Journal of Tuberculosis and Lung Disease”.Int J Tuberc Lung Dis. 11(8):868–875
[16] Notoatmojo.(2012). Metodologi Penelitian Kesehatan. Rineka Cipta, Jakarta.
[17] Ogboi, S. J.et al. (2010).“Socio-demographic characteristics of patients presenting pulmonary tuberculosis in a primary health centre, Zaria, Nigeria”. Journal of Medical Laboratory and Diagnosis.Vol. 1(2) pp. 11-14
[18] Reni, Wahyono,Yulismar (2016). “Kejadian Efek Samping Obat Anti Tuberkulosis pada Pasien Tuberkulosis”. J Respir Indo Vol.36: 222-30
[19] Rieder, M. &Ferro, A. (2015).“Adverse drug reactions”.The British Pharmacological Society (Br J Clin Pharmacol);80:4: 613–614
[20] Singh & Pant.(2014).“Adverse effects of first line antitubercular medicines on patients taking directly observed treatment short course: A hospital-based study". International Journal of Medicine and Public Health | Oct-Dec 2014| Vol 4 | Issue 4 :354-358
[21] Tudu, L.et al.(Juni 2017).“A Study on Socio Demographic Profile of PulmonaryTuberculosis Patients Attending Dots Centre of Field PracticeArea of Rajendra Institue of Medical Sciences, Jharkhand”.Journal of Dental and Medical Sciences (IOSR-JDMS).Volume 16, Issue 6 Ver. I, PP 126-130
[22] Kementerian Keseharan RI. (2014). Pedoman Nasional Pengendalian Tuberkulosis Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan.Kementerian Kesehatan Republik Indonesia.
[23] Perhimpunan Dokter Paru Indonesia. (2011).Tuberkulosis: pedoman diagnosis dan penatalaksanaan di Indonesia. Jakarta: Perhimpunan Dokter Paru Indonesia. 2-30.
[24] Sari, I.D. (2014).“Studi Monitoring Efek Samping Obat Antituberkulosis FDC Kategori 1 di Propinsi Banten dan Propinsi Jawa Barat”.Media Litbangkes Vol. 24 No. 1, Mar 2014, 28-35
[25] Sukandar, Hartini, Hasna. (2012). “Evaluasi Penggunaan Obat Tuberkulosis pada Pasien Rawat Inap di Ruang Perawatan Kelas III di Salah Satu Rumah Sakit di Bandung”.Acta Pharmaceutica Indonesia, Vol XXXVII, No 4, 153-158
[26] Veermaet al. (2014).“Adverse Drug Reactions Associated with First-Line Anti-Tubercular Drugs in A Tertiary Care Hospital of Central India: A Study of Clinical Presentations Causality and Severity”.Asian Journal of Pharmaceutical and Clical Research, Vol 7, issue 5
[27] WHO. (2015). Global Tuberculosis Report 2015. 20th edition.In France. World Health Organization
[28] Widjanarko, B.et al. (2009).“Factors that influence treatment adherence of tuberculosis patients living in Java, Indonesia”.Dove Press Journal : Patient Preference and Adherence;3 231–238
Downloads
Published
Issue
Section
License
Copyright (c) 2020 AUTHOR
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
